Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation-Reference-Cited by-同舟云学术

Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation

Published:2024-07 Issue:4 Volume:23 Page:685-689
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Aluma Bat El Bar^ORCID,Reiter Joel^ORCID,Efrati Ori,Bezalel Yael^ORCID,Keler Shlomit,Ashkenazi Moshe,Dagan Adi,Buchnik Yael,Sadras Ido^ORCID,Cohen-Cymberknoh Malena

Publisher

Elsevier BV

Reference29 articles.

1. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis;Costa;Orphanet J Rare Dis,2022

2. Triple therapy for cystic fibrosis Phe508del–gating and–residual function genotypes;Barry;N Engl J Med,2021

3. Elexacaftor–Tezacaftor–Ivacaftor for cystic fibrosis with a single Phe508del allele;Middleton;N Engl J Med,2019

4. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial;Heijerman;Lancet,2019

5. Sustained effectiveness of Elexacaftor-Tezacaftor-Ivacaftor in lung transplant candidates with cystic fibrosis;Martin;J Cyst Fibros,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies;Advances in Respiratory Medicine;2024-07-20

2. The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis;Journal of Cystic Fibrosis;2024-07